tiprankstipranks
TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Hong Kong Market

TOT BIOPHARM International Co. Ltd. (1875) Financial Statements

Compare
0 Followers

TOT BIOPHARM International Co. Ltd. Financial Overview

TOT BIOPHARM International Co. Ltd.'s market cap is currently HK$1.38B. The company's EPS TTM is HK$0.015; its P/E ratio is 114.74; TOT BIOPHARM International Co. Ltd. is scheduled to report earnings on March 25, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue¥ 780.63M¥ 442.18M¥ 76.33M¥ 22.49M¥ 45.31M
Gross Profit¥ 573.99M¥ 370.62M¥ 27.47M¥ 15.53M¥ 33.99M
Operating Income¥ -33.06M¥ -39.08M¥ -259.70M¥ -288.67M¥ -271.50M
EBITDA¥ 10.45M¥ -5.41M¥ -224.51M¥ -254.71M¥ -240.07M
Net Income¥ -37.76M¥ -49.92M¥ -261.22M¥ -288.50M¥ -331.18M
Balance Sheet
Cash & Short-Term Investments¥ 358.36M¥ 458.05M¥ 152.81M¥ 225.53M¥ 571.32M
Total Assets¥ 1.43B¥ 1.26B¥ 710.26M¥ 641.18M¥ 1.02B
Total Debt¥ 345.65M¥ 289.53M¥ 208.56M¥ 7.41M¥ 75.07M
Net Debt¥ -5.95M¥ -128.24M¥ 55.76M¥ -218.13M¥ -464.11M
Total Liabilities¥ 739.41M¥ 546.59M¥ 375.17M¥ 58.83M¥ 159.09M
Stockholders' Equity¥ 686.69M¥ 713.88M¥ 335.09M¥ 582.36M¥ 858.28M
Cash Flow
Free Cash Flow¥ -146.77M¥ -180.19M¥ -290.45M¥ -285.30M¥ -288.67M
Operating Cash Flow¥ 56.43M¥ 59.93M¥ -175.14M¥ -263.12M¥ -251.33M
Investing Cash Flow¥ -164.10M¥ -282.76M¥ -108.39M¥ 12.53M¥ -51.10M
Financing Cash Flow¥ 38.23M¥ 481.24M¥ 212.08M¥ -61.71M¥ 583.02M
Currency in CNY

TOT BIOPHARM International Co. Ltd. Earnings and Revenue History

TOT BIOPHARM International Co. Ltd. Debt to Assets

TOT BIOPHARM International Co. Ltd. Cash Flow

TOT BIOPHARM International Co. Ltd. Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis